Patents Examined by Wahwah T Johnson
-
Patent number: 11572553Abstract: A system for extracting analytes from a biological sample, which includes: an electronic pipette having pipette cones with a tip; a well support; a pipette holder including: a base which can removably house each well support; a pipette support into which the pipette is inserted, and which can move relative to the base between a first position in which the tips of the cones are inserted in a well of the support and at least one second position in which the tips are outside the wells; a housing facing the pipette cones above their tip when the pipette support is in the first position, and facing the tips of the pipette cones when the pipette support is in the second position; and a magnetized part removably inserted in the housing.Type: GrantFiled: November 25, 2016Date of Patent: February 7, 2023Assignee: BIOMÉRIEUXInventors: David Alix, Edgar Minassian, Jean-Claude Raymond, Philippe Wandels
-
Patent number: 11535894Abstract: Specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with deep vein thrombosis (DVT) and related pathologies, such as pulmonary embolism (PE).Type: GrantFiled: December 11, 2017Date of Patent: December 27, 2022Assignee: GENE GENDER S.R.L.Inventors: Goranka Tanackovic Abbas-Terki, Joëlle Michaud Schutz, Thierry Daniel Pache
-
Patent number: 11525163Abstract: The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.Type: GrantFiled: October 17, 2013Date of Patent: December 13, 2022Assignee: The Johns Hopkins UniversityInventors: Isaac Kinde, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis Diaz, Chetan Bettegowda, Yuxuan Wang
-
Patent number: 11492664Abstract: The present invention relates to methods of nucleic acid analyte detection by PCR. In particular, methods and kits for the detection of a plurality of nucleic acid analytes and the generation of kinetic signatures are provided. Further provided are methods and kits of nested PCR and PCR using limiting primers.Type: GrantFiled: August 1, 2018Date of Patent: November 8, 2022Assignee: California Institute of TechnologyInventors: Aditya Rajagopal, Emil P. Kartalov
-
Patent number: 11492655Abstract: A method of detecting a nucleic acid including a) mixing a solution containing a carboxylic acid and/or a salt thereof, a cerium oxide support and a sample containing a nucleic acid to adsorb said nucleic acid to said cerium oxide support, b) separating said cerium oxide support on which said nucleic acid was adsorbed from the mixture obtained in a), c) collecting said nucleic acid by adding an eluent to said cerium oxide support on which said nucleic acid was adsorbed and separated in b), and d) detecting said nucleic acid collected in c) by a hybridization reaction or a nucleic acid amplification reaction.Type: GrantFiled: November 10, 2017Date of Patent: November 8, 2022Assignee: Toray Industries, Inc.Inventors: Shota Sekiguchi, Mai Nakagawa, Masateru Ito, Shinjiro Sawada
-
Patent number: 11459618Abstract: A panel of gene expression markers for gastric cancer patient treated or to be treated by cetuximab is provided. Methods and compositions are also provided, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a gastric cancer patient's response to cetuximab.Type: GrantFiled: March 28, 2018Date of Patent: October 4, 2022Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Binchen Mao, Sheng Guo, Henry Qixiang Li
-
Patent number: 11441187Abstract: Disclosures herein encompass methods of treating a subject with moderate to severe hidradenitis suppurativa (HS) encompassing the determination of differential gene expression to characterize HS severity followed by administration of a treatment specific for the stage of HS severity characterized in the subject.Type: GrantFiled: October 4, 2019Date of Patent: September 13, 2022Assignee: The George Washington UniversityInventors: Victoria Shanmugam, Derek Jones
-
Patent number: 11427873Abstract: A method for characterizing tumor response to immune checkpoint blockade therapy, comprising: (i) obtaining tissue from the tumor; (ii) measuring, using the tissue, expression of one or more cell proliferation gene markers; (iii) determining, based on the measured expression of the one or more cell proliferation gene markers, a proliferation profile of the tumor; (iv) predicting, based on the determined proliferation profile, response of the tumor to immune checkpoint blockade therapy; and (v) determining, by a physician using the predicted response of the tumor to immune checkpoint blockade therapy, a therapy for the tumor.Type: GrantFiled: August 9, 2019Date of Patent: August 30, 2022Assignee: OmniSeq, Inc.Inventors: Carl Morrison, Sarabjot Pabla, Jeffrey Conroy, Sean Glenn
-
Patent number: 11421280Abstract: The present invention describes biomarkers that have been discovered to correlate with varied individual responses (e.g., efficacy, adverse effect, and other end points) to enzastaurin, in treating diseases such as, DLBCL, GBM, and other cancer types. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might not be beneficial, by the treatment.Type: GrantFiled: August 31, 2017Date of Patent: August 23, 2022Assignee: Denovo Biopharma, LLCInventors: Wen Luo, Hong Sun
-
Patent number: 11414715Abstract: Provided are methods and mRNA expression chips for identifying genes that are defined by certain nitrogen and water content relationships in soil. The genes can be up or down regulated under low nitrogen or arid conditions to increase the yield or biomass of crops.Type: GrantFiled: November 29, 2018Date of Patent: August 16, 2022Assignee: New York UniversityInventors: Gloria M. Coruzzi, Joseph Swift
-
Patent number: 11385233Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.Type: GrantFiled: December 21, 2018Date of Patent: July 12, 2022Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Paul Maciocia
-
Patent number: 11377691Abstract: The present invention relates to methods that use novel biomarkers for diagnosing and/or treating Kawasaki diseases. The novel biomarkers of the invention show altered cytosine methylations state of certain CpG loci in subject with Kawasaki Disease relative to subject without Kawasaki diseases. Also provided are kits comprising at least one primer or reagent specific for the altered cytosine methylation state of certain CpG loci to detect Kawasaki Disease.Type: GrantFiled: November 20, 2018Date of Patent: July 5, 2022Assignee: Chang Gung Memorial Hospital, KaohsiungInventors: Ying-Hsien Huang, Ho-Chang Kuo
-
Patent number: 11377692Abstract: Specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with deep vein thrombosis (DVT) and related pathologies, such as pulmonary embolism (PE), in relation with hormonal preparations (i.e. combined contraceptives, hormone replacement therapeutics) and hormone levels (i.e. during pregnancy and post-partum).Type: GrantFiled: December 11, 2017Date of Patent: July 5, 2022Assignee: GENE GENDER S.R.L.Inventors: Goranka Tanackovic Abbas-Terki, Joëlle Michaud Schutz, Thierry Daniel Pache
-
Patent number: 11339447Abstract: Provided in the disclosure relates to a panel of gene expression markers for cancer patient treated or to be treated by karenitecin. The disclosure provides methods and compositions, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a cancer patient's response to karenitecin. Such information can be used in determining prognosis and treatment options for cancer patients.Type: GrantFiled: March 28, 2018Date of Patent: May 24, 2022Assignee: CROWN BIOSCIENCE, INC. (TAICANG)Inventors: Binchen Mao, Dawei Chen, Sheng Guo, Henry Qixiang Li
-
Patent number: 11326158Abstract: Provided are methods and compositions for enriching cfDNA fragments from a biological fluid sample. A biological fluid sample, such as a urine sample, is collected and, in certain examples, pretreated before enrichment of the cfDNA. For the pretreatment, the sample is centrifuged to remove large cells and large cellular debris. As part of the pretreatment, the sample is also cleared of additional large cellular debris and excess volume by subjecting the sample to anion exchange chromatography and eluting bound DNA. Following any pretreatment of the sample, different concentrations an alcoholic solution are used—along with a mixture of DNA-binding particles and a chaotropic agent—to enrich the sample with cfDNA fragments having different sizes. For example, a biological sample can be enriched with small cfDNA fragments less than about 100 base pairs in length or large cfDNA fragments greater than about 100 base pairs in length.Type: GrantFiled: July 12, 2019Date of Patent: May 10, 2022Assignee: Myriad Women's Health, Inc.Inventors: Noah C. Welker, Clement S. Chu
-
Patent number: 11312998Abstract: Disclosed are methods of selecting a therapy for a cancer patient and methods of treating cancer in the patient. The methods comprise detecting a mutation in one or more genes in a cancer cell from the patient, wherein the one or more genes is selected from the group consisting of PTCD2, TWF1, DEFB134, BBS1, SOX10, APLNR, CD58, COL17A1, CRKL, hsa-mir-101-2, hsa-mir-548s, MAD2L1, MLANA, PSMB5, RNPS1, RPL10A, RPL23, SRP54, TAF3, TAP1, TAP2, TAPBP, TBXAS1, GMIP, OTOA, LAIR1, CLEC1, GPSM3, TRAF1, JAK2, TAPBPL, ICAM1, LILRA1, LILRA3, STAT1, and HLA-F. Also disclosed are methods of screening for one or more genes, the mutation of which confers resistance to T cell-mediated cytolytic activity.Type: GrantFiled: November 7, 2017Date of Patent: April 26, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Shashankkumar J. Patel, Nicholas P. Restifo
-
Patent number: 11293066Abstract: The present invention relates to a method for assessing the response to PD-1/PDL-1 targeting drugs based on the differential expression levels of BINP3 and GBE1.Type: GrantFiled: July 17, 2018Date of Patent: April 5, 2022Assignee: INSTITUT GUSTAVE ROUSSYInventors: Salem Chouaib, Stéphanie Buart
-
Patent number: 11274345Abstract: Methods for diagnosis of bacterial and viral infections are disclosed. In particular, the invention relates to the use of biomarkers that can determine whether a patient with acute inflammation has a bacterial or viral infection.Type: GrantFiled: June 5, 2017Date of Patent: March 15, 2022Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Purvesh Khatri, Timothy E. Sweeney
-
Patent number: 11235036Abstract: Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human LIPA gene. Some LIPA gene products have been discovered to be associated with reduced lysosomal acid lipase (LAL) activity.Type: GrantFiled: June 16, 2017Date of Patent: February 1, 2022Assignee: Alexion Pharmaceuticals, Inc.Inventors: Andrew Hutchinson, John V. W. Reynders, Guillermo del Angel, Nina Jain, Christen D. Forbes, Xiao-Qin Ren, Barbara Burton
-
Patent number: 11214838Abstract: The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.Type: GrantFiled: March 15, 2017Date of Patent: January 4, 2022Assignees: NATIONAL CANCER CENTER, H.U. Group Research Institute G.K.Inventors: Hirofumi Mukai, Toshikazu Ushijima, Satoshi Yamashita